Enjoy complimentary customisation on priority with our Enterprise License!
Some of the key findings from our adrenocortical carcinoma drugs market forecast report are summarized below
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The adrenocortical carcinoma drugs market has recorded the development of several advanced imaging techniques, which are non-invasive and exhibit enhanced diagnostic accuracy in the detection of adrenal lesions. For instance, unenhanced computed tomography adrenal densitometry is used to differentiate adrenal adenomas from malignant lesions based on the presence of intracellular lipids. A combination of positron emission tomography/computed tomography is also gaining popularity among end-users for the identification of malignant and benign lesions. Similarly, multiphase computed tomography technique is being used to calculate absolute and relative percentage washout, and thereby, differentiate between benign and malignant lesions. Such advances in imaging techniques for adrenal tumors are identified as one of the critical adrenocortical carcinoma drugs market trends responsible for the growth of the market.
Chemotherapeutics such as mitotane, paclitaxel, 5-fluorouracil, and vincristine are used to treat adrenocortical carcinoma. Mitotane is also used in combination with cisplatin, doxorubicin, and etoposide, to treat adrenocortical carcinoma. However, chemotherapeutics and combination therapy are associated with various side-effects, including nausea and vomiting, peripheral neuropathy, seizures, anemia, and risk of infections. Moreover, chemotherapeutics treatment for adrenocortical carcinoma has low survival rates. These factors have driven researchers to develop novel therapies, which have minimum side-effects and are highly efficacious in the treatment of adrenocortical carcinoma. Hence, the development, approval, and advantages of novel drugs over chemotherapeutics will drive the growth of the adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period.
The global adrenocortical carcinoma drugs market is concentrated. To help clients improve their market positions, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this adrenocortical carcinoma drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of several leading adrenocortical carcinoma drugs manufacturers, including:
The chemotherapy segment will account for the highest adrenocortical carcinoma drugs market share. The rising focus on the development of combination therapies to treat adrenocortical carcinoma will fuel the growth of the market segment over the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the adrenocortical carcinoma drugs market size.
With a complete study of the growth opportunities for the companies, it has been identified that North America will account for the highest share of the adrenocortical carcinoma drugs market throughout the forecast period. Factors such as the rising incidence of genetic syndromes, strong presence of vendors, and increasing R&D of drugs to treat adrenocortical carcinoma are responsible for adrenocortical carcinoma drugs market growth in this region.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.